# A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

> **NCT02943577** · PHASE3 · COMPLETED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 429 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Rapastinel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02943577
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-02
- **Primary completion:** 2018-10-26
- **Final completion:** 2018-11-21
- **Target enrollment:** 429 (ACTUAL)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02943577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02943577, "A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02943577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*